The Data Will See You Now! and Cystic Fibrosis Data is Valuable!
I was invited to speak at the PanagoraPharma Conference on Mobile Technology on June 28, 2017. I arrived first thing on Tuesday morning, slide set in hand. The 40th floor of Trade Tower 7 New York City is just as amazing as it sounds…but as I walked in, I was …
New drug (Thymosin alpha 1) discovery: potential for Cystic Fibrosis treatment
According to an article published on www.sciencedaily.com, researchers have discovered a potential new drug to treat and stop the progression of cystic fibrosis. While many other promising drugs are in the pipeline, we here at cysticfibrosis.com will be keeping a keen eye on further developments of this medication. Read the …
Treatment for Cystic Fibrosis: Vertex Acquires Concert’s CFTR Potentiator CTP-656
Vertex Pharmaceuticals recently purchased the Phase 2 cystic fibrosis potentiator drug CTP-656 from Concert Pharmaceuticals. The deal is estimated to be worth $250 million dollars. CTP-656 is intended to be a longer-acting, once daily version of Vertex’s drug ivacaftor, which aims to restore CFTR function in treatment for Cystic Fibrosis. …
New on our Cystic Fibrosis Social Media (@knowcf)
We are active on social media – want to know the latest news? Please follow the links to see what is new on our Cystic Fibrosis Social Media channels. Post your own comment – or just see what others are saying. February 2017 Facebook: Facebook.com/KnowCF Brian’s Genentech Pulmozyme Video: Click …
New on our Cystic Fibrosis Social Media (@knowcf)
We are active on social media – want to know the latest news? Please follow the links to see what is new on our Cystic Fibrosis Social Media channels. Post your own comment – or just see what others are saying. January 2017 Facebook: Facebook.com/KnowCF Facebook Member Post: A member of our …
ORKAMBI® (Lumacaftor/Ivacaftor) latest news: Germany, Australia availability
ORKAMBI® reimbursement agreement reached for Germany – December 19, 2016 Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation –(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has …
North American Cystic Fibrosis Conference 2016
The 30th annual North American Cystic Fibrosis Conference took place in October 2016 in Orlando, FL and offered more more than 60 sessions on topics related to CF. It was attended by physicians, research scientists, nurses, respiratory and physical therapists, social workers and pharmacists and more. The summary from the session …
Rare Disease Patient Advocacy Summit
Later this week, Jeanne Barnett will be attending the fifth annual RARE Patient Advocacy Summit run by Global Genes in Huntington Beach, California. The goal of this year’s RARE Patient Advocacy Summit is for patients, caregivers, and advocates to walk away equipped with actionable next steps whether you have been …
Barnyard Dust and Preventing Asthma in Children (one of many Cystic Fibrosis symptoms)
People with cystic fibrosis have infection and inflammation in their lungs, and some also have problems with asthma, making asthma one of the many cystic fibrosis symptoms that patients experience. From the CDC: the prevalence of asthma in the general population of the U.S. is 7-9%, and as many as …
SuperHero DNA
Study finds individuals immune to severe diseases. A new study has found that certain people’s genes have evolved in such a way that they are immune to certain severe inherited conditions. The study involved the analysis of previously collected DNA sets totaling 589,306 genomes from around the world with researchers hoping …